<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Buse, John</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Efficacy and Safety of Once-Weekly Exenatide versus Daily Liraglutide in Subjects with T2DM (DURATION-6)</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-11-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">13-14</style></pages><abstract><style  face="normal" font="default" size="100%">The Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects with Type 2 Diabetes [DURATION-6; NCT01029886] trial did not meet the prespecified primary endpoint that once-weekly injections of exenatide were noninferior to daily injections of liraglutide in reducing HbA1C in type 2 diabetes mellitus patients who were treated with lifestyle modification and oral antihyperglycemic medications.</style></abstract><number><style face="normal" font="default" size="100%">11</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>